Galapagos « Terug naar discussie overzicht

Galapagos juli 2017

2.236 Posts, Pagina: « 1 2 3 4 5 6 ... 91 92 93 94 95 96 97 98 99 100 101 ... 108 109 110 111 112 » | Laatste

Omlaag ↓

[verwijderd] 27 juli 2017 18:15

Ik had vroeger een oom die erg van fietszadels hield.

voda 27 juli 2017 18:21

quote:
Colonel Cluck schreef op 27 juli 2017 18:15:
Ik had vroeger een oom die erg van fietszadels hield.

Dames fietszadels? Vuile viezerik! :-)

www.youtube.com/watch?v=8T-6lkZRJvs

C200 27 juli 2017 18:46

In de US geloven ze niet zo in de cijfers:

80.92 -1.93 (-2.33%)
Real-time: 12:42PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD

Endless 27 juli 2017 19:27

quote:
C200 schreef op 27 juli 2017 18:46:
In de US geloven ze niet zo in de cijfers:

80.92 -1.93 (-2.33%)
Real-time: 12:42PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD

Volgens mij de cijfers niet essentie maar de vooruitgang en uitzichten van de medicatie er in nu vooral cash burn

C200 27 juli 2017 19:33

quote:
Endless schreef op 27 juli 2017 19:27:
[...]
Volgens mij de cijfers niet essentie maar de vooruitgang en uitzichten van de medicatie er in nu vooral cash burn

Inderdaad, ik ben benieuwd naar de cashburn. Kan best tegenvallen aangezien er meer in de pijplijn zit.

Daarnaast ben ik benieuwd hoeveel er is binnengekomen aan milestone betalingen.

Is de cashpositie nog steeds 1,3 miljard of is het minder? Of misschien wel meer?

Voor mij is het nu koffiedik kijken. (Best moeilijk met Senseo pads)

C200 27 juli 2017 19:35

Voorlopig gaat ie in de States door het putje:

80.02 -2.83 (-3.42%)
Real-time: 1:31PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD

Piet2010 27 juli 2017 19:47

met een volume van drie keer niets....

durobinet 27 juli 2017 19:51

De koersprijs is belangrijker dan het volume voor mij! :-)
En die is drie keer niets!

El buitre 27 juli 2017 20:50

Koers van Vertex gaat door het putje, nu 5.7%. Iemand een idee waarom? Lijkt erop dat GLPG meegenomen wordt in de daling.

MrMarket 27 juli 2017 20:51

Tech brede sell off in the USA, winstnemingen en zorgen over overvaluations, cijfers waren té goed allemaal...

MrMarket 27 juli 2017 20:56

In de S&P zitten ook tech fondsen dus vandaar dat die meegaat. De Dow houdt zich redelijk gemakkelijk vlak/groen

El buitre 27 juli 2017 20:58

Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales
Zacks.com, July 27, 2017, 08:59:00 AM EDT

Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2017 earnings per share of 10 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 6 cents. Notably, the company had posted a loss of 1 cent in the year-ago quarter. Strong product revenues led to higher profits in the quarter.

Excluding stock-based compensation expense, second-quarter adjusted earnings were 39 cents per share compared with the year-ago figure of 24 cents.

Vertex reported revenues of $544.1 million in the second quarter, up 26.1% year over year driven by strong product revenues. Revenues also beat the Zacks Consensus Estimate of $487.9 million by 11.5%.

CF Franchise Sales Strong

Vertex's second-quarter revenues consisted of sales from cystic fibrosis (CF) products - Kalydeco and Orkambi, collaborative ($27.3 million) and royalty revenues ($2.9 million). CF product revenues were $514 million in the second quarter, up 21% year over year.

Kalydeco sales rose 5% to $190 million gaining from inventory stocking of $5 million ahead of the Jul 4 holiday.

In May this year, Kalydeco was approved for use in CF patients 2 years and older who have one of 23 residual function mutations in the CFTR gene. More than 900 people in the U.S. have one of these mutations. The expanded indication should boost sales of the drug in future quarters.

Orkambi (lumacaftor/ivacaftor) delivered sales of $324.0 million, up 32% year over year. On a sequential basis, Orkambi sales rose almost 10% in the second quarter, supported by continued uptake globally and further uptake in the pediatric indication for which approval was received in Sep 2016. Meanwhile, an inventory stocking of $10 million ahead of the Jul4 holiday also benefited sales in the second quarter.

Costs Rise

Adjusted (including stock-based compensation expenses) research and development expenses increased 10% to $284.3 million in the second quarter due to higher costs related to development of triple combination CF regimens. Adjusted (including stock-based compensation expenses) selling, general and administrative (SG&A) expenses increased 10.7% to $121.7 million due to increased investment to support the global launch of Orkambi.

Maintains 2017 Guidance

Vertex maintained its 2017 guidance for Orkambi and Kalydeco sales but raised its guidance for combined operating costs.

Orkambi revenues are expected in the range of $1.1-$1.3 billion while Kalydeco revenues are estimated in the range of $740 million - $770 million. We remind investors that following the approval for the additional indication in May, Kalydeco 2017 revenue guidance was upped to $740 million - $770 million from $710 to $730 million. Total CF product revenues are expected in the range of $1.84 billion to $2.07 billion in 2017.

Combined adjusted research and development (R&D) and selling, general and administrative (SG&A) expenses in 2017 are anticipated in the range of $1.33 to $1.36 billion, higher than $1.25-$1.30 billion expected previously.

Costs are expected to be higher due to accelerated development of the triple combination CF pipeline and investment to develop CTP-656.

Focus on Triple Combination CF Regimens

Vertex is evaluating some next-generation CFTR correctors (VX-152, VX-440, VX-659 and VX-445) as part of a triple combination withVX-661 (tezacaftor) and ivacaftor.

Data from VX-152 and VX-440 phase II and VX-659 phase I triple combination studies, conducted on CF patients who have one F508del mutation and one minimal function mutation (F508del/Min), were presented last week. The data demonstrated that all three combinations led to pronounced improvement in lung function. In fact, these are the first data to show the potential to treat the underlying cause of CF in patients who have a severe and difficult-to-treat type of the disease.

Following discussions with regulatory agencies, Vertex will initiate pivotal phase III studies on one or two of the four triple combination regimens in the first half of 2018.

Other CF Pipeline Update

In March, positive data from two phase III studies - EVOLVE and EXPAND - evaluating Kalydeco in combination with VX-661 (tezacaftor) in CF patients with two copies of the F508del mutation were also announced. Both studies met their primary endpoints and demonstrated statistically significant improvements in lung function. Based on positive outcome from the studies, the company recently submitted regulatory applications in both the U.S. and EU. Encouragingly, the combination was also granted Orphan Drug designation by the FDA in June.

Earlier this week, Vertex announced that it has closed the previously announced agreement to buy Concert Pharmaceuticals, Inc.'s CNCE CF pipeline candidate, CTP-656. Vertex plans to develop CTP-656 for potential use in future once-daily regimens in combination with its other pipeline drugs to treat the underlying cause of CF.

Our Take

Vertex's second-quarter results were encouraging, topping estimates on both counts as sales of both its CF drugs rose.

Shares declined slightly in after-hours trading probably in response to the hike in operating costs expectations for the year. However, so far this year, Vertex's share priceis up a massive 121.8%, comparing favorably with an increase of 12% for the industry .

Meanwhile, Vertex's CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Its triple combination CF regimens are considered crucial for long-term growth. If the triple-combo regimes are successful, Vertex can address a significantly larger CF patient population- almost 90% of patients with CF - in the future.

However, one cannot forget potential competition for Vertex's triple combos. Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF.

Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surpris e

m.nasdaq.com/article/vertex-vrtx-q2-e...

[verwijderd] 27 juli 2017 21:03

quote:
BeursBonobo schreef op 27 juli 2017 20:51:
Tech brede sell off in the USA, winstnemingen en zorgen over overvaluations, cijfers waren té goed allemaal...

Wat bedoel je met "cijfers waren té goed allemaal"?

twopence 27 juli 2017 21:04

Koers op NASDAQ loop iets op. Mag van mij gauw terug naar 82 dollar. Anders zie ook ik het duister in.

[verwijderd] 27 juli 2017 21:05

daling: trump, healthcare stemming, trump, cijfers, trump.

Denk ik.

durobinet 27 juli 2017 21:11

En doemdenkers op IEX natuurlijk!!! ;-)

durobinet 27 juli 2017 21:13

By Alan Valdes, Director of Floor Operations at Silverbear Capital

What a week! Today began as another run at the all-time highs for the major indexes. But a JPMorgan (JPM) analyst note threw cold water on the rally. Marko Kolanovic highlighted the similarities between the current market and those in 1993 and 2000. Since the note was circulated by email, the Nasdaq has flipped into solidly negative territory while the VIX (^VIX, VXX) has soared by the largest amount in six weeks (hitting 11.26).

MrMarket 27 juli 2017 21:27

quote:
asti schreef op 27 juli 2017 21:03:
[...]
Wat bedoel je met "cijfers waren té goed allemaal"?

Cijfers erg goed, dus hoge stijgingen. Dus nu winstnemingen. Had het zelf morgen pas verwacht, jammer. Nu heb ik ze gehouden in verwachting van goed nieuws vanavond, maar ook dat redt ons niet uit het rood morgen vrees ik

EDIT: als er nou maar geen negatief nieuws komt iig..

[verwijderd] 27 juli 2017 21:31

en niet alleen dat, er is vandaag ook nog een healthcare stemming. No 3 in twee dagen, en in totaal ben ik de tel kwijt.

En Mooch blijkt een tweede rangs mafioso te speln, bedeigt Reince met lekken van openbare informatie, trump flikkert transies onder de bus, laat boy scouts oud-presidenten uitjouwen en vertelt ze rond het kampvuur wat oude rijke racistische mannen doen op een jacht (wink wink, know what I mean),Beauregard Sessions gooit alle homo's onder de trein, Min van Binnenlandse zaken bedreigt senatoren uit Alaska als ze niet stemmen zoals trump wil, belastingplannen kunnen ze vergeten voor 2017, budget is non-existened, debt ceiling vergeten we gemakshalve....

Enige plus puntje is dat we sinds deze week weten dat Betsy DeVos kan lezen.

Het gaat goed in de USA

durobinet 27 juli 2017 22:01

Tja, wat doe je daar eigenlijk Cluck?

2.236 Posts, Pagina: « 1 2 3 4 5 6 ... 91 92 93 94 95 96 97 98 99 100 101 ... 108 109 110 111 112 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	10 mei 2024 17:35
Koers	26,660
Verschil	-0,160 (-0,60%)
Hoog	26,920
Laag	26,660
Volume	44.236
Volume gemiddeld	85.274
Volume gisteren	45.851

Galapagos nieuws

07 mei	Beursblik: UBS verlaagt koersdoel Gal...
03 mei	Beursblik: hoge cashburn Galapagos	1
02 mei	Galapagos handhaaft verwachte cashburn
01 mei	Aandeelhouders Galapagos keuren alle ...
12 apr	KBC Securities verlaagt koersdoel Gal...
05 apr	Galapagos toont innovatieve aanpak in...
23 feb	AEX op de waakvlam het weekend in, ko...	2
23 feb	Beursblik: gebrek aan opwaarts potent...
23 feb	Gaat AEX op recordjacht of gaat de be...
23 feb	Update : Galapagos voldoet aan verwac...

Meer ››